Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Segundo Mariz

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Orphanet Journal of Rare Diseases|October 8, 2015
Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Nature Reviews. Drug Discovery|June 2, 2016
Worldwide collaboration for orphan drug designationSegundo Mariz, James H Reese, Kerstin Westermark, et al.
Frontiers in Oncology|January 6, 2022
Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan DesignationJorn Mulder, Tobias van Rossum, Segundo Mariz, et al.
Drug Discovery Today|June 26, 2017
Establishing rarity in the context of orphan medicinal product designation in the European UnionStelios Tsigkos, Matthias Philipp Hofer, Maria Elzbieta Sheean, et al.
Archives of Disease in Childhood|November 2, 2017
Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designationsAndrea Ecker, Segundo Mariz, Frauke Naumann-Winter, et al.
Orphanet Journal of Rare Diseases|December 6, 2014
Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Orphanet Journal of Rare Diseases|January 28, 2014
Use of biomarkers in the context of orphan medicines designation in the European UnionStelios Tsigkos, Jordi Llinares, Segundo Mariz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2024
Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in EuropeGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2023
The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal ProductsGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.
Gene Therapy|March 14, 2024
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designationMaria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Orphanet Journal of Rare Diseases|October 8, 2015
Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Nature Reviews. Drug Discovery|June 2, 2016
Worldwide collaboration for orphan drug designationSegundo Mariz, James H Reese, Kerstin Westermark, et al.
Frontiers in Oncology|January 6, 2022
Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan DesignationJorn Mulder, Tobias van Rossum, Segundo Mariz, et al.
Drug Discovery Today|June 26, 2017
Establishing rarity in the context of orphan medicinal product designation in the European UnionStelios Tsigkos, Matthias Philipp Hofer, Maria Elzbieta Sheean, et al.
Archives of Disease in Childhood|November 2, 2017
Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designationsAndrea Ecker, Segundo Mariz, Frauke Naumann-Winter, et al.
Orphanet Journal of Rare Diseases|December 6, 2014
Establishing medical plausibility in the context of orphan medicines designation in the European UnionStelios Tsigkos, Segundo Mariz, Jordi Llinares, et al.
Orphanet Journal of Rare Diseases|January 28, 2014
Use of biomarkers in the context of orphan medicines designation in the European UnionStelios Tsigkos, Jordi Llinares, Segundo Mariz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2024
Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in EuropeGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2023
The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal ProductsGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.
Gene Therapy|March 14, 2024
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designationMaria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, et al.
Pageof 3